# A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Source: https://onco.cc/trials/nct06732323/  
OnCo record `nct06732323` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing ESG401 in triple-negative breast cancer, now recruiting.

## Summary

A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer is a phase 3 interventional study registered as NCT06732323, led by Qilu Pharmaceutical, and recruiting on the registry. Official title: A Randomised, Open-label, Phase III Study of ESG401 Versus Investigator's Choice Chemotherapy as First-line Treatment in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer. Planned enrolment is 504 participants (estimated). The study started in 2025-09-04 and primary completion is expected in 2027-06. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06732323
- Phase: 3
- Setting: A Randomized, Open-label, Phase III Study of ESG401 Versus Investigator's Choice Chemotherapy as First-line Treatment in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
- Sponsor: Qilu Pharmaceutical
- Enrolled: 504

## Sources

- ClinicalTrials.gov NCT06732323: https://clinicaltrials.gov/study/NCT06732323

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [ESG401](https://onco.cc/drugs/esg401/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct06732323.json